Finally, the dose–response curves (Figure 1F) confirmed that despite these differences in the response patterns, both tumor types responded to treatment with rTBL-1, although EGFR− cells presented a 21.69% higher tolerance than EGFR+ cells in terms of their LC50, at 23.50 μg of rTBL-1/mL for MC-38 cells and 30.01 μg of rTBL-1/mL for CT-26 cells. Here, EGFR is linked to neoplasm.